Enhancement of solubility and bioavailability of modafinil using nanoparticles
Introduction
Modafinil is a CNS stimulant that promotes wakefulness. Modafinil is used in the treatment of narcolepsy, ADHD (Attention Deficient Hyperactivity Disorder), shift work sleep disorder, hypersomnia and excessive daytime sleepiness. The chemical name for modafinil is 2-[(diphenylmethyl)sulfinyl]acetamide that belongs to BCS Class-II with low solubility and high permeability. The absolute bioavailability of modafinil is not clear due to its aqueous insolubility (Robertson & Hellriegel, 2003). However, in-vitro modafinil binds to the dopamine transporter and inhibits dopamine reuptake, this activity has been associated with in-vivo with increased extracellular dopamine.
For BCS Class-II substances the bioavailability may be enhanced by increasing the solubility of drug and its dissolution rate in gastro intestinal fluid (Khadka et al., 2014). Considering the drugs with low solubility, the relation between dissolution rate and absorption is very distinct. Improvement of drug solubility thereby increasing its bioavailability is the most challenging aspect of drug development. Many techniques have been made to modify the dissolution characteristics of drugs to attain more rapid absorption.
Particle size reduction is a physical modification technique in which the size of drug particle can be reduced by techniques like micronization and nanonization (nanotechnology). In nanotechnology the particle size of drug can be reduced to nanoscale level, by different methods of preparation of nanoparticles such as nanoencapsulation, nanosuspension, nanoprecipitation, etc., Nanoencapsulation of drug is the method of preparing loaded particles in the size range of 1 to 1000 nm (Malodia, Singh, Mishra, & Shrivastava, 2012). Nanoencapsulation includes both nanospheres and nanocapsules. Nanospheres are matrix type of system in which the drug may be absorbed to the surface or encapsulated within the particle (polymer) (Reis, Neufeld, Ribeiro, & Veiga, 2006).
The present study is an approach for improving the solubility characteristic of modafinil. For this, polymeric nanoparticles were prepared by ionic-gelation method in which chitosan is used as polymer and tripolyphosphate (TPP) is used as cross linking agent (Ahirrao, Gide, Shrivastav, & Sharma, 2014). The best formulation has been choosed and lyophilized to obtain solid nanoparticles of modafinil and tablets were prepared and compared with the in-vitro characteristics of marketed tablet of modafinil.
Materials and Methods
Modafinil (Free sample); Acetic acid, Sodium tripolyphosphate [TPP], Povidone, Talc (Loba Chemie); Chitosan, Magnesium stearate (HI-media Laboratries); Crosspovidone (Yarrow Chem Products).
Melting pointing and solubility
Melting point of the drug was determined using digital melting point apparatus in which a capillary tube fused at one end was placed with drug and introduced in the melting point viewer and the degree at which the drug melted was noted down. Test for solubility was performed by dissolving minimum quantity of drug in various solvents (Jigar, Jayvadan, & Jain, 2012).
Calibration Study – UV Spectroscopy Study
Modafinil standard stock solution was prepared by dissolving 100mg of modafinil in 10ml of ethanol and sonicated for 10 minutes and the solution was made upto 100ml using 0.1 N Hydrochloric acid (1000µg/ml). 10ml of prepared solution was diluted to 100ml using 0.1 N Hcl (100µg/ml). To form concentration of 1µg/ml, 1ml of 100µg/ml stock solution was diluted to 10ml with 0.1 N Hcl and scanned using UV visible spectrophotometer in the spectrum mode between the wavelength ranges of 200nm to 400nm, to determine the maximum absorbance (Mahapatra, Murthy, Biswal, Mahapatra, & Pradhan, 2011).
The prepared stock solution was serially diluted to get different concentrations 2, 4, 6, 8 and 10µg/ml to determine the linearity range. The standard samples were analyzed at 222nm using UV Spectrophotometer.
Formulation of modafinil nanoparticles
Modafinil polymeric nanoparticles were prepared by ionic-gelation method. Chitosan solution of concentrations 0.25, 0.50 & 0.75% was prepared by dissolving the required quantities of chitosanin 0.1% acetic acid and allowed to stir for 6 hours under magnetic stirring and the solution was allowed to set constant for upto 18 hours. TPP solution of concentrations 0.50, 1 & 1.5% was prepared by dissolving the weighed quantities of TPP in 100ml of distilled water and kept under magnetic stirring for 15 minutes.Chitosan solution was taken in a beaker and the pH of solution was adjusted to pH 4.5-5.5, to this solution 100mg of modafinil was added and dissolved and the pH of solution was maintained between 4.5-5.5.
The above prepared solution was constantly kept in magnetic stirrer to this, a mixture of TPP was added dropwise with constant stirring and allowed for 30 minutes (Agarwal et al., 2018; Fàbregas et al., 2013; Grenha, 2012; Kunjachan & Jose, 2010; Papadimitriou, Bikiaris, Avgoustakis, Karavas, & Georgarakis, 2008).
Formulation code |
Drug |
Polymer |
TPP |
---|---|---|---|
F1 |
1 |
0.25 |
0.25 |
F2 |
1 |
0.25 |
0.50 |
F3 |
1 |
0.25 |
0.75 |
F4 |
1 |
0.50 |
0.25 |
F5 |
1 |
0.50 |
0.50 |
F6 |
1 |
0.50 |
0.75 |
F7 |
1 |
0.75 |
0.25 |
F8 |
1 |
0.75 |
0.50 |
F9 |
1 |
0.75 |
0.75 |
Chitosan and TPP were added in the ratio of 6:1. Table 1 shows nine different formulations with three different ratios of chitosan and TPP for modafinil nanoparticles.
Evaluation of prepared modafinil nanoparticles
Particle size and polydispersity index (PDI)
Particle size and PDI value were determined using Zetasizer (Nano ZS90, Malvern Instruments) at 25° C. For the measurement of particle size and PDI value the samples were kept in polystyrene cuvette and the readings were found out at a fixed angle.
Zeta potential
The electrophoretic mobility (zeta potential) measurement of polymeric nano-particles was done by using Zetasizer (Nano ZS90, Malvern Instruments). The samples were placed in a polystyrene cuvette (at 25 °C) combined with Zeta dip cell was used to measure the potential.
Entrapment efficiency
2 ml of the formulation was taken and centrifuged at 12,000 rpm 60 minutes. The supernatant was recovered using micro pipette and was analyzed under UV spectrophotometer at 222nm
Encapsulation efficiency (%) =
Lyophilization technique
Entrapment efficiency, particle size and zeta potential were taken as important factors and based on their values best formulation was selected. The selected formulations were kept in well closed containers and allowed to freeze under -80° C for 4 hours. Then the formulations were kept in Lyodel freeze drier at -40° C.
Characterization of freeze dried formulation of modafinil nanoparticle - SEM analysis
The surface morphology of lyophilized nanoparticle was observed using SEM (Scanning Electron Microscopy). The stub containing sample was placed in the chamber of scanning electron microscope to confirm the particles are in nano range (Heera & Shanmugam, 2015).
Preparation of modafinil nanoparticle tablets
Modafinil tablets were prepared by direct compression method. Cross-Povidone, Povidone, Talc and Magnesium Stearate were added respectively as disintegrant, binder, glidant and lubricant to this formulation in different concentrations and compressed into tablets (Bushra, 2018; Upadhyay & Gupta, 2018).Table 2 shows the formulationsprepared for tablets loaded with modafinil nanoparticles.
Formulation code |
Formulation F7(mg) |
Tablet excipients |
|||
---|---|---|---|---|---|
Povidone |
Cross-povidone |
Talc |
Magnesium stearate |
||
FT1 |
100 |
15 |
10 |
20 |
5 |
FT2 |
100 |
15 |
15 |
15 |
5 |
FT3 |
100 |
25 |
10 |
10 |
5 |
FT4 |
100 |
25 |
15 |
5 |
5 |
Evaluation of prepared modafinil nanoparticle loaded tablet
Thickness and diameter
Thickness and Diameter of the tablet is important for the uniformity of the tablet size. Tablets are selected and thickness of the tablet was measured by using Screw Gauge and Vernier Caliper apparatus.
Weight variation test
The prepared tablets were individually weighed using electronic balance and the test was performed and the deviation was calculated with respect to average weight. The percentage deviation of tablets between the weight 80 mg – 250 mg is ± 7.5% as per pharmacopoeial limits.
Hardness test
The prepared tablets were subjected to hardness test which was determined using Pfizer hardness tester and it was measured in kg/cm2.
Disintegration test
Disintegration test for the prepared tablets was performed using Basket-rack assembly. One tablet was placed in each of the basket and the test was performed using 0.1N Hcl buffer as the immersion fluid maintained at 37± 2° C. Time for completely disintegrated tablets was noted.
Formulation Code |
Particle size (nm) |
PDI |
Zeta potential (mV) |
Entrapment efficiency(%) |
---|---|---|---|---|
F1 |
280 |
0.516 |
24.5 |
60 |
F2 |
176 |
0.382 |
16.1 |
64 |
F3 |
403 |
0.502 |
25.4 |
67 |
F4 |
538 |
0.830 |
13.4 |
65 |
F5 |
549 |
0.137 |
16.3 |
70 |
F6 |
237 |
0.513 |
21.4 |
63 |
F7 |
155 |
0.280 |
30.3 |
80 |
F8 |
113 |
0.294 |
28.3 |
74 |
F9 |
271 |
0.499 |
21.1 |
76 |
Formulation code |
Average thickness (mm) |
Average diameter (cm) |
---|---|---|
FT1 |
4.02 |
1.2 |
FT2 |
4.04 |
1.4 |
FT3 |
4.05 |
1.5 |
FT4 |
4.04 |
1.4 |
Formulation code |
Average weight of tablets (mg) |
% Deviation |
---|---|---|
FT1 |
178.73 |
-0.005 |
FT2 |
178.93 |
0.072 |
FT3 |
178.70 |
0 |
FT4 |
178.93 |
0.072 |
Formulation code |
Hardness value(kg/cm2) |
Disintegration time (min) |
---|---|---|
FT1 |
5.5 |
10 |
FT2 |
4.2 |
8 |
FT3 |
6.5 |
17 |
FT4 |
6.2 |
15 |
Time (min) |
% Drug release of prepared tablets |
% Drug release of marketed tablet |
|||
---|---|---|---|---|---|
FT1 |
FT2 |
FT3 |
FT4 |
||
0 |
0 |
0 |
0 |
0 |
0 |
5 |
25.58 |
54.41 |
40.07 |
28.96 |
59.24 |
10 |
31.38 |
63.11 |
44.75 |
30.57 |
61.5 |
15 |
38.14 |
66.49 |
47.81 |
39.43 |
64.72 |
20 |
42.17 |
72.61 |
49.09 |
44.42 |
69.715 |
25 |
49.58 |
79.86 |
51.67 |
48.13 |
72.61 |
30 |
56.5 |
85.17 |
54.09 |
51.03 |
74.86 |
45 |
61.98 |
90.16 |
56.5 |
53.44 |
77.44 |
60 |
68.1 |
97.41 |
58.44 |
61.98 |
80.0226 |
Dissolution test
Dissolution studies were carried out by using USP-II dissolution test apparatus. The paddle was rotated at 50 rpm and depth of 25 mm in a buffer volume of 900ml. Dissolution testing, was carried out using buffer of pH 1.2 representing the stomach pH. Samples were periodically and it was replaced with fresh buffer in order to maintain sink conditions. The samples were filtered through filter paper and diluted to suitable concentration. Then, the samples were analyzed using UV-spectrophotometer at 222nm.
Based on the above three factors, tablet formulation FT3 was selected as best formulation and the in-vitro characteristics of FT3 was compared with marketed modafinil tablet.
In-vitro release study of marketed modafinil tablet
Same dissolution procedure followed to the prepared modafinil nanoparticle loaded tablet was followed to the marketed tablet of modafinil, using USP-II apparatus, rotated at 50 rpm in buffer volume of 900 ml using buffer of pH 1.2. Samples were periodically taken and replaced with fresh buffer at required time intervals. The samples were filtered, diluted to equivalent concentration and analyzed at 222 nm using UV spectrophotometer.
Results and Discussion
Melting point is found to be 165° C which confirms Modafinil drug. Solubility of modafinil in different solvent was carried out and found that modafinil is soluble in acetic acid (150mg/ml) and slightly soluble in ethanol (10mg/ml).
The prepared stock solution of modafinil was scanned in UV-Visible spectrophotometer from 200 – 400 nm and the maximum wavelength occurs at 222nm that is shown in Figure 1 and it is selected as the maximum absorbance.
A series of concentrations of solution 2, 4, 6, 8 and 10µg/ml were prepared and the absorbances were noted at 222nm using UV spectrophotometer.The standard graph of modafinil is plotted in Figure 2. The regression value was found to be 0.997 from the graph.
Particle size and PDI were determined by photon correlation spectroscopy using Zetasizer (Nano ZS 90, Malvern instruments) at 25° C. Reduction in particle size enhances the rate of dissolution and PDI is the degree of particle size distribution, narrow the particle size distribution prevents the particle growth and maintains the stability. The zeta potential value determines the physical stability of the formulation. A minimum zeta potential value of ±30mV is required, whereas a minimum zeta potential of ±20mV is desirable. Entrapment efficiency is the amount of drug entrapped within in the formulation that was found out by centrifuging the 2 ml of formulation at 12,000 rpm for 60 minutes and analyzing the supernatant under UV spectroscopy at 222 nm. The amount of drug entrapped can be calculated by measuring the unbound free drug in the supernatant. Particle size, PDI, Zeta potential and Entrapment Efficiency of formulations are listed in Table 3.
Formulation – F7 was choosed as the best formulation showing higher entrapment efficiency (%) of 80% and 155 nm of particle size with PDI value of 0.280 as shown in Figure 3 and zeta potential value with +30.3 mV as shown in Figure 4.
Morphological studies of modafinil nanoparticles were performed and shown Figure 5 using Scanning Electron Microscope. The image of SEM depends on signal produced by elastic and inelastic interactions between high energy electron beam and specimen surface.
Evaluation of prepared modafinil nanoparticle loaded tablets
Thickness and Diameter of the tablets was measured by using Screw Guage and Vernier Caliper apparatus and the average readings were tabulated in the following Table 4. The percentage weight variation for all formulations was performed. The percentage deviation of tablets between the weight 80 mg – 250 mg is ± 7.5% as per pharmacopoeial limits. All the formulations passed the weight variation test as per the limits as shown in the Table 5. The hardness of prepared tablets were determined using Pfizer hardness tester. Hardness of the tablet is the indication of its strength against resistance of tablet. The hardness values of tablets of reported in Table 7. The average range of tablets prepared tablets are between 2 – 8 kg/cm2. The prepared individual tablets of each formulation were tested for disintegration which in turn is the time required for the tablet to get finely dissolved in gastric tract, the disintegration time of each batch of tablet is listed in Table 6. Immediate release tablets disintegrate within a time a 15 minute.
In-vitro release study of marketed and prepared modafinil tablet
Dissolution studies were performed by USP-II type apparatus at speed of 50 rpm in 0.1 N Hcl buffer and drug release was calculated, which shows the drug release of four formulation of nanoparticle loaded tablet that is represented in Table 7 and Figure 6. From the parameters of hardness, disintegration and dissolution test formulation (FT2) was selected as best formulation. In-vitro dissolution studies were performed for the marketed tablet of modafinil under the same conditions prescribed to dissolution test of prepared nanoparticle loaded modafinil tablet. The release profile data of marketed tablet and FT2 formulated tablet where compared and the formulated tablet showed a better release. Drug release profile of marketed tablet is figured and tabulated in Table 7 and Figure 7.
Conclusion
From the above studies, it was concluded that Modafinil tablets loaded with polymeric nanoparticles of modafinil prepared by ionic-gelation has better solubility. Comparing the dissolution profile of prepared nanoparticle loaded modafinil tablet with the marketed tablet, the prepared tablet shows 97% drug release in an hour and proves 0.21 fold better drug release than marketed tablet. This confirms the enhanced solubility of modafinil, which may be useful confirmation for suggesting future study on increase in bioavailability of modafinil in animal study.